Xu XL - Search Results

1

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy.

Song Y, Dong QQ, Ni YK, Xu XL, Chen CX, Chen W. Song Y, et al. Among authors: xu xl. Int J Nanomedicine. 2024 Jun 12;19:5739-5761. doi: 10.2147/IJN.S448684. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38882545 Free PMC article. Review.

2

The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis.

Xu XL, Chen SZ, Chen W, Zheng WH, Xia XH, Yang HJ, Li B, Mao WM. Xu XL, et al. Breast Cancer Res Treat. 2013 Jun;139(2):329-39. doi: 10.1007/s10549-013-2563-5. Epub 2013 May 14. Breast Cancer Res Treat. 2013. PMID: 23670132

3

The overexpression of VEGF in esophageal cancer is associated with a more advanced TMN stage: a meta-analysis.

Xu XL, Ling ZQ, Chen W, Xu YP, Mao WM. Xu XL, et al. Among authors: xu yp. Cancer Biomark. 2013;13(2):105-13. doi: 10.3233/CBM-130343. Cancer Biomark. 2013. PMID: 23838139

4

The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.

Xu XL, Zhang YP, Fang Y, Su D, Chen W, Feng JG, Li ZP, Mao WM. Xu XL, et al. J Cancer Res Ther. 2015 Aug;11 Suppl 1:C49-55. doi: 10.4103/0973-1482.163839. J Cancer Res Ther. 2015. PMID: 26323924 Free article.

5

Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review.

Xu XL, Dan L, Chen W, Zhu SM, Mao WM. Xu XL, et al. Onco Targets Ther. 2016 Feb 22;9:845-53. doi: 10.2147/OTT.S95511. eCollection 2016. Onco Targets Ther. 2016. PMID: 26955282 Free PMC article.

6

Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer.

Lei T, Xu XL, Chen W, Xu YP, Mao WM. Lei T, et al. Among authors: xu xl, xu yp. Onco Targets Ther. 2016 Feb 24;9:921-8. doi: 10.2147/OTT.S95517. eCollection 2016. Onco Targets Ther. 2016. PMID: 26966380 Free PMC article.

7

MR molecular imaging of HCC employing a regulated ferritin gene carried by a modified polycation vector.

Zhang Q, Lu Y, Xu X, Li S, Du Y, Yu R. Zhang Q, et al. Int J Nanomedicine. 2019 May 2;14:3189-3201. doi: 10.2147/IJN.S191270. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31118631 Free PMC article.

8

Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo.

Sun MC, Xu XL, Lou XF, Du YZ. Sun MC, et al. Among authors: xu xl. Int J Nanomedicine. 2020 May 8;15:3267-3279. doi: 10.2147/IJN.S245326. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32440123 Free PMC article. Review.

9

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.

Qi J, Jin F, Xu X, Du Y. Qi J, et al. Int J Nanomedicine. 2021 Feb 22;16:1435-1456. doi: 10.2147/IJN.S285999. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33654395 Free PMC article. Review.

10

Nanomaterials-Based Photodynamic Therapy with Combined Treatment Improves Antitumor Efficacy Through Boosting Immunogenic Cell Death.

Jin F, Liu D, Xu X, Ji J, Du Y. Jin F, et al. Int J Nanomedicine. 2021 Jul 8;16:4693-4712. doi: 10.2147/IJN.S314506. eCollection 2021. Int J Nanomedicine. 2021. PMID: 34267518 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,139 results

Search Page

Filters